Is Semaglutide FDA approved?
This profile records Semaglutide as FDA approved.
MORE CONTEXT ›
Approval can be specific to a formulation, indication, and prescribing context, so review the regulatory and source details on this page.
Metabolic CATEGORY
Semaglutide
THE APPETITE CONTROLLER
Ozempic; Wegovy; Rybelsus
Semaglutide is an FDA-approved GLP-1 receptor agonist that has transformed treatment of obesity and type 2 diabetes. It works by mimicking the hormone GLP-1 to reduce appetite, slow stomach emptying, and improve insulin sensitivity. In trials, it produced 15% weight loss and significantly reduced cardiovascular events. Available as weekly injection (Ozempic/Wegovy) or daily oral tablet (Rybelsus).
Semaglutide
Semaglutide
Semaglutide
Semaglutide Evidence Snapshot
How these guides are reviewed
REGULATORY STATUS
FDA-approved uses exist
DOSING GUIDANCE
Reviewed by our clinical team
LINKED EVIDENCE
1 research sources
CONTENT UPDATED
Aug 28, 2026
Dose and schedule recommendations shown below come from The Peptide App Clinical Team. Research links are provided so readers can inspect the supporting evidence directly. Review the sources.
Quick Answers About Semaglutide
What dose does The Peptide App Clinical Team recommend for Semaglutide?
Dose: Injection: Start 0.25 mg weekly, titrate to 1-2.4 mg weekly.
MORE CONTEXT ›
Oral: Start 3 mg daily, up to 14 mg daily. Schedule: weekly. Cycle: Ongoing as prescribed. This is clinical-team guidance for reference and does not replace individualized instructions from a licensed clinician.
What research supports this Semaglutide guide?
This guide links to 1 curated or current research sources.
MORE CONTEXT ›
Open the research section to inspect the source titles, publication details, study types, and available abstracts directly.
Studied Effects & Mechanisms
Appetite Suppression
Activates hypothalamic POMC neurons to reduce hunger
Insulin Enhancement
Stimulates glucose-dependent insulin secretion
Gastric Slowing
Delays stomach emptying for prolonged fullness
Cardioprotection
Reduces cardiovascular events and inflammation
Those with type 2 diabetes
People with BMI over 30 (obesity)
Those with BMI over 27 with weight-related conditions
Anyone wanting proven, FDA-approved weight loss
Those at high cardiovascular risk
Semaglutide Research
Live research temporarily unavailableThe live research feed did not return papers for this page. The curated references below remain available for crawlable source context.
RESEARCH REFERENCES